Table 6 Completed or undergoing clinical trials on inhibitors of several predominant NK cell-associated checkpoints
Targets | Agents | Cancer types | Phase | NCT number | Status |
|---|---|---|---|---|---|
NKG2A | Monalizumab | Hematological or solid tumors | 2 | NCT04333914 | Completed |
LA-HNSCC | 2 | NCT03410030 | Not yet recruiting | ||
S095029 | Solid tumors | 1 | NCT05162755 | Recruiting | |
HY-0102 | Solid tumors | 1 | NCT04914351 | Active, not recruiting | |
KIR | IPH2101 | MM | 1 | NCT01217203 | Completed |
2 | NCT00999830 | Completed | |||
2 | NCT01222286 | Completed | |||
AML | 1 | NCT01256073 | Completed | ||
Lirilumab | Solid tumors | 1/2 | NCT01714739 | Completed | |
Hematological malignancy | 2 | NCT02481297 | Completed | ||
IPH4102 | T Cell Lymphoma | 2 | NCT03902184 | Recruiting | |
LIR1 | AGEN1571 | Solid tumors | 1 | NCT05377528 | Recruiting |
TIGIT | Belrestotug | Solid tumors | 2 | NCT03739710 | Recruiting |
1/2 | NCT05060432 | Recruiting | |||
MM | 1/2 | NCT05289492 | Recruiting | ||
BMS-986207 | MM | 1/2 | NCT04150965 | Recruiting | |
Solid tumors | 1/2 | NCT04570839 | Active, not recruiting | ||
Vibostolimab | Melanoma | 1/2 | NCT04303169 | Recruiting | |
1/2 | NCT04305041 | Recruiting | |||
1/2 | NCT04305054 | Recruiting | |||
3 | NCT05665595 | Recruiting | |||
Domvanalimab | NSCLC | 3 | NCT04736173 | Recruiting | |
2 | NCT04791839 | Recruiting | |||
2 | NCT05676931 | Recruiting | |||
Melanoma | 2 | NCT05130177 | Recruiting | ||
Gastrointestinal tract carcinoma | 2 | NCT05329766 | Recruiting | ||
Upper gastrointestinal tract adenocarcinoma | 3 | NCT05568095 | Recruiting | ||
NSCLC | 2 | NCT04262856 | Active, not recruiting | ||
M6223 | Urothelial carcinoma | 2 | NCT05327530 | Recruiting | |
CHS-006 | Solid tumors | 1/2 | NCT05757492 | Recruiting | |
Tiragolumab | Solid tumors | 2 | NCT03708224 | Recruiting | |
NSCLC | 3 | NCT04294810 | Recruiting | ||
ESCC | 3 | NCT04543617 | Recruiting | ||
Rectal cancer | 2 | NCT05009069 | Recruiting | ||
Renal cell carcinoma | 2 | NCT05805501 | Recruiting | ||
NSCLC | 2 | NCT03563716 | Active, not recruiting | ||
SCLC | 3 | NCT04256421 | Active, not recruiting | ||
Gastric cancer | 2 | NCT04933227 | Active, not recruiting | ||
1/2 | NCT05251948 | Active, not recruiting | |||
Ociperlimab | ESCC | 2 | NCT04732494 | Recruiting | |
NSCLC | 3 | NCT04746924 | Recruiting | ||
3 | NCT04866017 | Recruiting | |||
2 | NCT05014815 | Recruiting | |||
Biliary tract carcinoma | 2 | NCT05023109 | Recruiting | ||
Cervical cancer | 2 | NCT04693234 | Active, not recruiting | ||
Limited-stage SCLC | 2 | NCT04952597 | Active, not recruiting | ||
SEA-TGT | NSCLC | 2 | NCT04585815 | Active, not recruiting | |
Etigilimab | Solid tumors | 1/2 | NCT04761198 | Active, not recruiting | |
Ovarian, primary peritoneal, or fallopian tube cancer | 2 | NCT05026606 | Active, not recruiting | ||
AZD2936 | NSCLC | 2 | NCT04995523 | Recruiting | |
Gastric cancer | 2 | NCT05702229 | Recruiting | ||
HLX301 | Solid tumors | 1/2 | NCT05102214 | Recruiting | |
Lymphoma or solid tumors | 1/2 | NCT05390528 | Recruiting | ||
HB0036 | Solid tumors | 1/2 | NCT05417321 | Recruiting | |
B7H3 | Omburtamab | CNS tumors | 1 | NCT01502917 | Completed |
Peritoneal cancer | 2 | NCT04022213 | Recruiting | ||
CNS tumors | 2/3 | NCT03275402 | Active, not recruiting | ||
2 | NCT04743661 | Active, not recruiting | |||
Ifinatamab deruxtecan | Solid tumors | 1/2 | NCT04145622 | Recruiting | |
Extensive-stage SCLC | 2 | NCT05280470 | Active, not recruiting | ||
Vobramitamab duocarmazine | Prostatic cancer | 2/3 | NCT05551117 | Recruiting | |
Enoblituzumab | Prostate cancer | 2 | NCT02923180 | Active, not recruiting |